MTD not reached in ongoing phase I trials of PKI-166, an EGF receptor tyrosine kinase inhibitor Nov. 6, 2001
Raf kinase inhibitor Bay-43-9006 advances through phase I trials without significant toxicity Nov. 5, 2001
RSS